Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: Indirect finding of vascular reparative therapy?

European Heart Journal

Volumn 33, Issue 11, 2012, Pages 1325-1333

  Brugaletta, Salvatore ^a,b   Heo, Jung Ho ^a   Garcia Garcia, Hector M ^a,c   Farooq, Vasim ^a   Van Geuns, Robert Jan ^a   De Bruyne, Bernard ^d   Dudek, Dariusz ^e   Smits, Pieter C ^f   Koolen, Jacques ^g   McClean, Dougal ^h   Dorange, Cecile ⁱ   Veldhof, Susan ⁱ   Rapoza, Richard ⁱ   Onuma, Yoshinobu ^a   Bruining, Nico ^a   Ormiston, John A ^j   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CARDIALYSIS   (Netherlands)

^d CARDIOVASCULAR CENTER   (Belgium)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f Maasstad Hospital Rotterdam   (Netherlands)

^g CATHARINA HOSPITAL   (Netherlands)

^h CHRISTCHURCH HOSPITAL   (New Zealand)

ⁱ ABBOTT VASCULAR   (United States)

^j AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

ABSORB BVS; Echogenicity; Vasomotion; VH

Indexed keywords

ACETYLCHOLINE; EVEROLIMUS; GLYCERYL TRINITRATE; POLYLACTIDE; POLYMER;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIORESORBABLE VASCULAR SCAFFOLD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY; CORONARY ARTERY DISEASE; DEVICES; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEART CATHETER; HISTOLOGY; HUMAN; IMAGING SYSTEM; IMPLANTATION; INTRACORONARY INFUSION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RADIOFREQUENCY; SILENT MYOCARDIAL INFARCTION; THERAPY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASCULAR REPARATIVE THERAPY; VASODILATATION;

ABSORBABLE IMPLANTS; ACETYLCHOLINE; AGED; CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NITROGLYCERIN; PLAQUE, ATHEROSCLEROTIC; SIROLIMUS; TISSUE SCAFFOLDS; VASODILATION; VASODILATOR AGENTS; VASOMOTOR SYSTEM;

EID: 84861794182     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr466     Document Type: Article

References (30)

1. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371: 899-907. (Pubitemid 351384734)
2. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
3. Khattab A, Windecker S. Vascular restoration therapy: what should the clinical and angiographic measures for success be? EuroIntervention 2009;5(Suppl. F): F49-F57.
4. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-1588.
5. Sarno G, Bruining N, Onuma Y, Garg S, Brugaletta S, De Winter S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Garcia-Garcia HM, Ormiston JA, Serruys PW. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int J Cardiovasc Imaging 2011. Published online ahead of print.
6. Lavi S, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, Holmes DR Jr, Lerman A. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart 2009;95: 1525-1530.
7. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122: 2301-2312.
8. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007;69:128-131. (Pubitemid 46052603)
9. Okamura T, Garg S, Gutierrez-Chico JL, Shin ES, Onuma Y, Garcia HM, Rapoza R, Sudhir K, Regar E, Serruys PW. In-vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the Revision 1.0 and Revision 1.1 stent design in the ABSORB clinical trial. Euro-Intervention 2010;5:932-938.
10. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122:2288-2300.
11. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002;106:2200-2206. (Pubitemid 35222213)
12. Bruining N, de Winter S, Roelandt JR, Regar E, Heller I, van Domburg RT, Hamers R, Onuma Y, Dudek D, Webster MW, Thuesen L, Ormiston JA, CheongWF, Miquel-Hebert K, Veldhof S, Serruys PW. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc Interv 2010;3:449-456.
13. Brugaletta S, Gomez-Lara J, Serruys PW, Farooq V, van Geuns RJ, Thuesen L, Dudek D, Koolen J, Chevalier B, McClean D, Windecker S, Smits P, De Bruyne B, Whitbourn R, Meredith I, van Domburg R, Sihan K, de Winter S, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM, Ormiston J, Bruining N. Serial in vivo IVUS-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation. Insights from ABSORB B trial. JACC Cardiovasc Interv 2011;4:1281-1289.
14. Bruining N, Verheye S, Knaapen M, Somers P, Roelandt JR, Regar E, Heller I, de Winter S, Ligthart J, Van Langenhove G, de Feijter PJ, Serruys PW, Hamers R. Three-dimensional and quantitative analysis of atherosclerotic plaque composition by automated differential echogenicity. Catheter Cardiovasc Interv 2007;70: 968-978.
15. Reiber JH, Serruys PJ. Quantitative coronary angiography: methodologies. Quantitative Coronary Angiography. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996. p98-102.
16. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166-170. (Pubitemid 43069032)
17. Brugaletta S, Garcia-Garcia HM, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin ES, Van Geuns RJ, De Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston J, Serruys P. Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. Eurointervention 2011;6:1110-1116.
18. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-1778. (Pubitemid 37296082)
19. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, King SB 3rd, Robinson KA, Chronos NA, Hou D. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv 2009;2:253-262.
20. Sarno G, Onuma Y, Garcia Garcia HM, Garg S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Ormiston JA, Serruys PW. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 2010;75: 914-918.
21. Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, van Geuns RJ, McClean D, Dudek D, Thuesen L, Chevalier B, Windecker S, Whitbourn R, Dorange C, Miquel-Hebert K, Sudhir K, Ormiston JA, Serruys PW. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging 2011;27:859-866.
22. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoprotein-associated phospholipase A (2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182.
23. Hong MK, Park DW, Lee CW, Lee SW, Kim YH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv 2009;2:679-688.
24. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-236. (Pubitemid 40966848)
25. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, Lim SM, Jeon DS, Chung WS, Baek SH, Lee MY. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007;48:553-567.
26. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323. (Pubitemid 37186209)
27. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, Ntalianis A, Muller O, Barbato E, Beleslin B, Sagic D, De Bruyne B, Bartunek J, WijnsW. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv 2008;1:193-200.
28. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135. (Pubitemid 34155123)
29. Verheye S, MartinetW, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007;49:706-715. (Pubitemid 46205042)
30. Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 2007;3:241-244. (Pubitemid 46752686)